BEAM Stock — Beam Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.

Source: 10-K FY2025 via SEC EDGAR

Share price

$26.41

Market cap

$2,733.3M

Cash

$1,043.9M

Enterprise value

$1,789.8M

Balance sheet

Cash	$1,043.9M
Debt	$100.4M
Net cash	$943.5M
Enterprise value	$1,789.8M
Basic shares	103.5M shares
Fully diluted shares	125.2M shares
Fully diluted market cap	$3,307.0M
Cash per share	$10.09
Quarterly burn	$66.1M
Cash runway	17.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

103.3M

Pre-funded warrants

1.4M

Options

12.6M

RSUs

3.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

4.5M

FDSO

125.2M

Cap table as of 2026-06-30.

Price history

Loading BEAM daily closes…

Loading price history…

Next catalyst

BEAM-301 · Est. Nov 7, 2026 · guidance midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now guidance midpoint	BEAM-301 Initial clinical data	Not disclosed	Not disclosed	2026
GUIDEDDec 1-31 in 24d	risto-cel Updated BEACON trial data	Not disclosed	Not disclosed	by year-end 2026
GUIDEDDec 1-31 in 24d	risto-cel BLA submission	Not disclosed	Not disclosed	as early as year-end 2026
Jan 12 - Feb 23 in 9 wks	BEAM-201	Phase 2	Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia	—
Feb 10 - Mar 23 in 15 mo	BEAM-301: Single dose of BEAM-301 administered by IV	Phase 2	Glycogen Storage Disease Type Ia	—
Mar 14 - Apr 25 in 16 mo	BEAM-101	Phase 2	Sickle Cell Disease	—
Jun 12 - Jul 24 in 19 mo	BEAM-302	Phase 2	Alpha 1-Antitrypsin Deficiency	—
Jul 11 - Aug 22 in 33 mo	Allogeneic anti-CD7 CAR-T cells (BEAM-201)	Phase 1	T-Cell Acute Lymphoblastic Leukemia/Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ristocel

Phase 1 · Active Modality: ex vivo autologous HSC base editing

Aliases risto-cel, formerly BEAM-101

Target HBG1/HBG2

Indications

Sickle cell disease (SCD) (Phase 1)

Catalysts

— as early as year-end 2026

Status note Lead program; Phase 1/2 BEACON trial ongoing. Base edits mimic hereditary persistence of fetal hemoglobin (HPFH) SNPs to raise HbF. One patient death reported (respiratory failure, 4 months post-infusion). In vivo HSC-targeted LNP is the next-wave approach for SCD (lead optimization).

BEAM-302

Phase 1 · Active Modality: in vivo LNP base editing (liver-targeted)

Target SERPINA1

Indications

Alpha-1 antitrypsin deficiency (AATD) (Phase 1)

Status note Corrects the E342K (PiZZ) mutation in a one-time treatment. Phase 1/2 open-label trial ongoing (Part A lung disease, Part B liver disease). FDA alignment on a potential accelerated approval pathway based on AAT biomarkers over 12 months; dose selection for registrational development to be finalized on trial data.

BEAM-301

Phase 1 · Active Modality: in vivo LNP base editing (liver-targeted)

Target G6PC

Indications

Glycogen storage disease type 1a (GSDIa) (Phase 1)

Catalysts

— 2026

Status note Corrects the R83C mutation in G6PC; open-label, multi-cohort single-ascending-dose Phase 1/2 in the U.S.

BEAM-304

Preclinical · Active Modality: in vivo LNP base editing (liver-targeted)

Target PAH

Indications

Phenylketonuria (PKU) (Preclinical)

Catalysts

— 2026

Status note Newly announced; initial development targets the two most prevalent PAH variants (R408W first).

BEAM-103

Phase 1 · Active Modality: anti-CD117 monoclonal antibody

Target CD117

Indications

not disclosed (Stage not disclosed)

Status note Enables the ESCAPE platform (non-genotoxic conditioning); Phase 1 healthy volunteer trial, dosing completion expected 1H 2026.

Pfizer collaboration development candidate (undisclosed)

Stage not disclosed · Active Modality: in vivo base editing (liver-targeted)

Partnerships Pfizer: exclusive worldwide license opt-in exercised December 2025 on a liver-targeted development candidate from the 2021 research collaboration (three rare-genetic-disease targets)

Status note Pfizer opted in at completion of the 4-year research term; no target or stage disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	BEAM-201
Lead indication	Lymphoblastic Lymphoma
Lead phase	Phase 2
Active trials	6
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05885464	Phase 2	Active, not recruiting	Sponsor	BEAM	—	Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia	—
NCT06735755	Phase 2	Recruiting	Sponsor	BEAM	—	Glycogen Storage Disease Type Ia	2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)
NCT05456880	Phase 2	Active, not recruiting	Sponsor	BEAM	—	Sickle Cell Disease	—
NCT06389877	Phase 2	Recruiting	Sponsor	BEAM	—	Alpha 1-Antitrypsin Deficiency	—
NCT07304791	Phase 1	Recruiting	Sponsor	BEAM	—	Healthy Subjects; Healthy Participant Study	—
NCT07373639	Not disclosed	Recruiting	Sponsor	BEAM	—	Hemoglobinopathy; Sickle Cell Disease	—
NCT06934382	Phase 1	Recruiting	Collaborator	Stephan Grupp MD PhD	—	T-Cell Acute Lymphoblastic Leukemia/Lymphoma	—
NCT06071377	Not disclosed	Recruiting	Collaborator	National Alliance for Sickle Cell Centers	—	Sickle Cell Trait	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 8 active trials for Beam Therapeutics Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Casdin Capital	1,350,000	no change	2.32%	2026-08-14
RTW Investments	570,394	no change	0.17%	2026-08-14
ADAR1 Capital Management	0	-1,446,375	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

BEAM — Beam Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

BEAM — Beam Therapeutics Inc.